{"id":46320,"date":"2023-10-01T07:22:26","date_gmt":"2023-10-01T07:22:26","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=46320"},"modified":"2023-10-10T14:45:48","modified_gmt":"2023-10-10T14:45:48","slug":"eu-approves-cabotegravir-as-injectable-prep","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/46320","title":{"rendered":"EU approves cabotegravir as injectable PrEP"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 19 September 2023, ViiV Healthcare issued a press release that the European Union had approved cabotegravir as HIV pre-exposure prophylaxis (PrEP).<\/strong><\/p>\n<p>Approval includes both the two-monthly injection and oral tablet formulations of cabotegravir.\u00a0Injections are given every two months.<\/p>\n<p>The indication is for use by\u00a0adults and adolescents (age 12 and older), weighing at least 35 kg who are at high risk of sexual exposure to HIV.<\/p>\n<p>However, the long half-life of the injections means that significant levels of cabotegravir can continue at detectable levels for more than a year. People who continue to need PrEP after using cabotegravir injections are recommended to switch to oral PrEP for the following year.<\/p>\n<p>Injectable cabotegravir is produced by ViiV Healthcare and marketed under the trade name Apretude<em>.<\/em><\/p>\n<p>No details about pricing were included in the announcement.<\/p>\n<p>Reference<\/p>\n<p>ViiV Healthcare press statement.\u00a0European Commission authorises ViiV Healthcare\u2019s <em>Apretude<\/em>(cabotegravir long-acting and tablets) for HIV prevention. (19 September 2023).<br \/>\n<a href=\"https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2023\/september\/european-commission-authorises-viiv-healthcare\/\">https:\/\/viivhealthcare.com\/hiv-news-and-media\/news\/press-releases\/2023\/september\/european-commission-authorises-viiv-healthcare\/<\/a><\/p>\n<p><em>This report was first posted on 19 September 2023.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 19 September 2023, ViiV Healthcare issued a press release that the European Union had approved cabotegravir as HIV pre-exposure prophylaxis (PrEP). Approval includes both the two-monthly injection and oral tablet formulations of cabotegravir.\u00a0Injections are given &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-46320","post","type-post","status-publish","format-standard","hentry","category-transmission-and-prevention"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=46320"}],"version-history":[{"count":13,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46320\/revisions"}],"predecessor-version":[{"id":46522,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/46320\/revisions\/46522"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=46320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=46320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=46320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}